ANB 010
Alternative Names: ANB-010Latest Information Update: 12 Jan 2024
At a glance
- Originator Biocad
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor VIII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Haemophilia A
Most Recent Events
- 03 Jan 2024 ANB 010 is available for licensing as of 03 Jan 2024. https://biocadglobal.com/partnering (Biocad pipeline, January 2024)
- 08 Aug 2023 Ministry of Health of the Russian Federation authorises the clinical study for Haemophilia A before August 2023
- 26 Jul 2023 Phase-I/II clinical trials in Haemophilia A in Russia (Parenteral) (NCT06185335)